Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

1



Comparative evaluation of combination of metformin and glimepiride with that of metformin and sitagliptin in type 2 diabetes mellitus with respect to glycemic targets

Mohammad Anjoom, Shaktibala Dutta, Mirza Atif Beg, Amit Varma, Shalu Bawa, Ravi Kant.

Abstract
Background: Sitagliptin, an oral and selective dipeptidyl peptidase-4 inhibitor, represents a novel therapeutic approach for the treatment of type 2 diabetes mellitus. Metformin and glimepiride are most commonly used oral hypoglycemic agents.

Objective: To compare combination of metformin and glimepiride with that of metformin and sitagliptin in patients with type 2 diabetes mellitus.

Materials and Methods: The study was conducted by Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, India, in Medicine OPD for 1 year. Total 60 patients with type 2 diabetes mellitus were included in the study. The patients were divided into two groups: Group I (n = 30), patients were put on metformin 500 mg + glimepiride 1 mg once daily and Group II, (n = 30), patients were put on metformin 500 + sitagliptin 50 mg once daily. The patients were stabilized for 2 weeks and followed up every 6 weeks for 24 weeks. Fasting blood sugar (FBS) and postprandial blood sugar (PPBS) were measured at every follow-up; glycosylated hemoglobin (HbA1c) was measured at 0 and 24 weeks. Analysis was done using t-test, and a p-value of 0.05), PPBS (p < 0.05), and HbA1c (p > 0.05) was done. Most common adverse drug reactions were hypoglycemia, abdominal discomfort, weight loss, and nausea/vomiting.

Conclusion: Both groups showed significant improvement in FBS, PPBS, and HbA1c at the end of the study period. Intergroup comparison showed significant improvement in PPG in group II (with a combination of metformin and sitagliptin) at the end of the study.

Key words: Type 2 diabetes mellitus, DPP-4 inhibitors, novel therapeutic approach, HbA1c



Share this Article


Advertisement
Journal of Behavioral Health

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons